David Johnson work email
- Valid
- Valid
- Valid
- Valid
David Johnson personal email
- Valid
David Johnson phone numbers
Dr. David Johnson is an inventor, entrepreneur, and expert in genomics with a track record of bringing new medical technologies to the clinic and the market. Dr. Johnson is Founder and CEO of GigaMune, which is developing novel technology for in vivo targeted gene delivery of T cell receptors (TCRs) and chimeric antigen receptors (CARs) to treat serious diseases such as cancer and autoimmune diseases. Our vision is to bring gene therapy into mainstream medicine through in vivo delivery of any gene to any cell in any tissue location. Our initial goal is to challenge conventional ex vivo cell therapy manufacturing by reducing costs and improving outcomes. Previously, Dr. Johnson brought GigaGen's massively diverse recombinant polyclonal antibody drugs from concept to clinic, including three INDs and over $100 million in government contracts. Dr. Johnson led negotiation and sale of the company to Grifols for a company valuation of $142.9 million (with potential for further product-related earnout) in March 2021. Also, Dr. Johnson was among the founding members and COO of Natera (NASDAQ: NTRA), a molecular diagnostics firm recently valued at $9 billion. Prior to Natera he was the ENCODE Project Director at the Stanford Human Genome Center. Dr. Johnson holds a BS in Biology from Duke University, a PhD in Genetics from Stanford University, and an MBA from the Haas School of Business at the University of California, Berkeley.
-
Founder And CeoGigamune Jan 2022 - PresentGigaMune is developing novel technology for in vivo targeted gene delivery of T cell receptors (TCRs) and chimeric antigen receptors (CARs) to treat serious diseases such as cancer and autoimmune diseases. Our vision is to bring gene therapy into mainstream medicine through in vivo delivery of any gene to any cell in any tissue location. Our initial goal is to challenge conventional ex vivo cell therapy manufacturing by reducing costs and improving outcomes. See our high throughput immune screening technology highlighted in Nature Biotechnology (DOI: 10.1038/s41587-020-0438-y), and our petabase-scale protein search algorithm, published in Nature (DOI: 10.1038/s41586-021-04332-2). -
Angel InvestorEl Poblenou Llc Feb 2022 - PresentSan Francisco, Ca, UsEl Poblenou LLC is my private office investing in early stage biotechnology companies. I am particularly interested to back first-time technical entrepreneurs where I can provide value as an adviser. My investments include FormaPath (https://www.formapath.com/), Tensor Bio (https://www.tensorbio.com/), and Lynx Bio (https://www.lynx.bio/). -
Entrepreneur In ResidenceIllumina Ventures Feb 2022 - Feb 2023Illumina Ventures is an independently managed firm focused on early-stage companies that are pioneering new applications of genomics and enabling precision medicine. We invest in life science tools, clinical diagnostics, therapeutics, and other opportunities to improve human health. Our strategic relationship with Illumina provides us access to the expertise and vision of the world's leading genomics solutions provider. -
Founder And CeoGigagen, Inc May 2010 - Oct 2021San Carlos, California, UsHeadquartered in South San Francisco, CA, GigaGen is advancing transformative antibody drugs for immune deficiency, infectious diseases and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies. GigaGen’s novel technology platforms uniquely capture and recreate complete immune repertoires as functional antibody libraries. This approach enabled the creation of first-in-class recombinant polyclonal antibody therapies for the treatment of infectious diseases, including GigaGen’s lead clinical asset GIGA-2050 for COVID-19, which contains more than 12,000 anti-coronavirus antibodies.GigaGen’s lead oncology asset, GIGA-564, is a clinical stage anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action. GigaGen is leveraging its proprietary technology platforms for the continued discovery of novel recombinant polyclonal drugs and monoclonal antibodies to treat life-threatening diseases.GigaGen was acquired by Grifols, S.A., at a valuation of $142.9 million with the potential for further product-related payments. -
Chief Operating Officer, Svp Of Research And DevelopmentNatera Jan 2006 - May 2010Austin, Texas, UsDirected development and delivery of reproductive genetics laboratory service products that rapidly dominated the market, and improved clinical outcomes.Natera (NASDAQ: NTRA) provides molecular diagnostic services for reproductive genetic medicine, especially in vitro fertilization and noninvasive prenatal diagnosis. At Natera, I was on the founding team and invented several key technologies. I went on to direct product development, product research, clinical research, and laboratory operations. It was also my responsibility to interface with commercial team, opinion leaders, and customers to ensure that services met the highest standards. I hired, trained, and managed 15 technical employees, including five PhDs. My job was also to troubleshoot and solve technical and operational deficiencies. I became a published leader in the field, and was an invited speaker at several national and international meetings.Key Achievements:• Built a molecular diagnostics lab from concept to clinical testing within one year.• Scaled lab to win 30% market share one year after launch.• Secured >$1.6 million in nondilutive financing through NIH/NICHD.• Negotiated commercial partnerships with Ferring Pharmaceutical and Illumina.• Published clinical findings in Molecular Human Reproduction and Human Reproduction. -
Encode Project DirectorStanford University Medical Center Jan 2006 - Nov 2007Palo Alto, California, UsDirected production genomics research group with $1 million annual budget and internationally recognized stature.The Stanford Human Genome Center used the latest molecular genomic technologies to sequence and characterize the function of human genomes. ENCODE is an international consortium of genomics labs, with the intent of characterizing the function of every nucleotide in the human genome. There, I led Stanford's contribution to the consortium, presented at meetings, managed external collaborations. Directed internal research operations and staff, designed and interpreted experiments. Also, I acted as primary bioinformatics and biostatistics analyst for all ENCODE-related experimental data. Invented new technologies and interfaced with corporate partners.Key Achievements:• Invented a novel genomic measurement technology (ChIP-seq), now used by 200+ labs globally.• Wrote a successful $14.6 million research grant from NIH for large-scale ChIP-seq experiments.• Successfully negotiated research collaborations with Solexa (acquired by Illumina).• Published findings in Science, Genome Research, and Nature Methods.
David Johnson Skills
David Johnson Education Details
-
Stanford UniversityGenetics -
University Of California, Berkeley, Haas School Of BusinessMaster Of Business Administration (Mba)
-
Duke UniversityBiology
-
Penn State UniversityApplied Statistics
-
Tokyo Institute Of TechnologyGenetics
-
Universidad San Francisco De QuitoBiology
Frequently Asked Questions about David Johnson
What company does David Johnson work for?
David Johnson works for Gigamune
What is David Johnson's role at the current company?
David Johnson's current role is Founder and CEO at GigaMune.
What is David Johnson's email address?
David Johnson's email address is dj****@****gen.com
What is David Johnson's direct phone number?
David Johnson's direct phone number is +141597*****
What schools did David Johnson attend?
David Johnson attended Stanford University, University Of California, Berkeley, Haas School Of Business, Duke University, Penn State University, Tokyo Institute Of Technology, Universidad San Francisco De Quito.
What skills is David Johnson known for?
David Johnson has skills like Biotechnology, Genomics, Molecular Biology, Start Ups, Bioinformatics, Entrepreneurship, Commercialization, Immunology, Product Development, Business Development, Cancer, Leadership.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial